Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.
Google ScholarÂ
Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021;137:1377–91.
Google ScholarÂ
Gong X, Li C, Wang Y, Rao Q, Mi Y, Wang M, et al. Mature plasmacytoid dendritic cells associated with acute myeloid leukemia show similar genetic mutations and expression profiles to leukemia cells. Blood Sci. 2022;4:38–43.
Google ScholarÂ
Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, et al. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019;33:2466–80.
Google ScholarÂ
Rickmann M, Krauter J, Stamer K, Heuser M, Salguero G, Mischak-Weissinger E, et al. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann Hematol. 2011;90:1047–58.
Google ScholarÂ
Hamadeh F, Awadallah A, Meyerson HJ, Beck RC. Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation. Cytometry B Clin Cytom. 2020;98:43–51.
Google ScholarÂ
Wang W., Xu J., Khoury J. D., Pemmaraju N., Fang H., Miranda R. N., et al. Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers. 2022;14:3375.
Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, et al. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica. 2021;106:3056–66.
Google ScholarÂ
Zhu L, Wang P, Zhang W, Li Q, Xiong J, Li J, et al. Plasmacytoid Dendritic Cell Infiltration in Acute Myeloid Leukemia. Cancer Manag Res. 2020;12:11411–9.
Google ScholarÂ
Huang Y, Wang Y, Chang Y, Yuan X, Hao L, Shi H, et al. Myeloid Neoplasms with Elevated Plasmacytoid Dendritic Cell Differentiation Reflect the Maturation Process of Dendritic Cells. Cytometry A. 2020;97:61–9.
Google ScholarÂ
Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380:1628–37.
Google ScholarÂ
Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124:385–92.
Google ScholarÂ
Boichut M, Poussard M, Roussel X, Belakri I, Biichlé S, Fredon M, et al. New leads to enhance tagraxofusp efficacy in pDC-AML. Blood Neoplasia. 2025;2:100066.
Google ScholarÂ
Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15:471–85.
Google ScholarÂ
Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000;165:6037–46.
Google ScholarÂ
Reizis B. Plasmacytoid Dendritic Cells: Development, Regulation, and Function. Immunity. 2019;50:37–50.
Google ScholarÂ
Åšniegocka M, Liccardo F, Fazi F, Masciarelli S. Understanding ER homeostasis and the UPR to enhance treatment efficacy of acute myeloid leukemia. Drug Resist Updat. 2022;64:100853.
Google ScholarÂ
Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21:421–38.
Google ScholarÂ
Janssens S, Pulendran B, Lambrecht BN. Emerging functions of the unfolded protein response in immunity. Nat Immunol. 2014;15:910–9.
Google ScholarÂ
Chaudhary V., Ah Kioon M. D., Hwang S. M., Mishra B., Lakin K., Kirou K. A., et al. Chronic activation of pDCs in autoimmunity is linked to dysregulated ER stress and metabolic responses. J Exp Med. 2022;219:e20221085.
Iwakoshi NN, Pypaert M, Glimcher LH. The transcription factor XBP-1 is essential for the development and survival of dendritic cells. J Exp Med. 2007;204:2267–75.
Google ScholarÂ
Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, et al. ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell. 2015;161:1527–38.
Google ScholarÂ
Li K, Du Y, Cai Y, Liu W, Lv Y, Huang B, et al. Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia. Leukemia. 2023;37:308–25.
Google ScholarÂ
Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4:27–42.
Google ScholarÂ
Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433–7.
Google ScholarÂ
Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21:71–88.
Google ScholarÂ
Jousse C, Deval C, Maurin AC, Parry L, Chérasse Y, Chaveroux C, et al. TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway. J Biol Chem. 2007;282:15851–61.
Google ScholarÂ
Beisel C, Ziegler S, Martrus Zapater G, Chapel A, Griesbeck M, Hildebrandt H, et al. TLR7-mediated activation of XBP1 correlates with the IFNα production in humans. Cytokine. 2017;94:55–8.
Google ScholarÂ
Staron M, Yang Y, Liu B, Li J, Shen Y, Zúñiga-Pflücker JC, et al. gp96, an endoplasmic reticulum master chaperone for integrins and Toll-like receptors, selectively regulates early T and B lymphopoiesis. Blood. 2010;115:2380–90.
Google ScholarÂ
Monti M, Ferrari G, Gazzurelli L, Bugatti M, Facchetti F, Vermi W. Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling. J Exp Clin Cancer Res. 2024;43:196.
Google ScholarÂ
Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M. Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity. 2010;33:955–66.
Google ScholarÂ
Yang L, Li S, Chen L, Zhang Y. Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity. Cancer Biol Med. 2023;20:728–47.
Google ScholarÂ
Qiu G, Xu X, Xue H, Zhang T, Xuan L, Liu Q. CD74 + Leukemia-Associated Macrophages Supporess T Cell Immune Surveillance and Promote Leukemic Cell Growth in Acute Myeloid Leukemia. Blood. 2023;142:289.
Google ScholarÂ
Chen G, Wang W, Wei X, Chen Y, Peng L, Qu R, et al. Single-cell transcriptomic analysis reveals that the APP-CD74 axis promotes immunosuppression and progression of testicular tumors. J Pathol. 2024;264:250–69.
Google ScholarÂ
Ma C, Chen J, Ji J, Zheng Y, Liu Y, Wang J, et al. Therapeutic modulation of APP-CD74 axis can activate phagocytosis of TAMs in GBM. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167449.
Google ScholarÂ
Cohen Shvefel S, Pai JA, Cao Y, Pal LR, Bartok O, Levy R, et al. Temporal genomic analysis of homogeneous tumor models reveals key regulators of immune evasion in melanoma. Cancer Discov. 2025;15:553–77.
Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408–17.
Google ScholarÂ
Elsässer A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, et al. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene. 2003;22:5646–57.
Google ScholarÂ
Zhou C, Martinez E, Di Marcantonio D, Solanki-Patel N, Aghayev T, Peri S, et al. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia. 2017;31:1196–205.
Google ScholarÂ
Sun H, Lin DC, Guo X, Kharabi Masouleh B, Gery S, Cao Q, et al. Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 2016;7:18736–49.
Google ScholarÂ
Na Y, Hall A, Yu Y, Hu L, Choi K, Burgard JA, et al. Runx1/3-driven adaptive endoplasmic reticulum stress pathways contribute to neurofibromagenesis. Oncogene. 2023;42:1038–47.
Google ScholarÂ
Wang JP, An CC, Wang ZN, Wei ZJ, Dai Y. The Identification of LA-tumor associated macrophages in immune modulation via amyloid-beta precursor protein/CD74 signal pathway in gastric cancer: a predictive module and machine learning. Front Oncol. 2025;15:1752562.
Google ScholarÂ
Jiang L, Yu G, Meng W, Wang Z, Meng F, Ma W. Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumour Biol. 2013;34:629–36.
Google ScholarÂ
Yu G, Yin C, Jiang L, Xu D, Zheng Z, Wang Z, et al. Amyloid precursor protein has clinical and prognostic significance in AML1-ETO-positive acute myeloid leukemia. Oncol Lett. 2018;15:917–25.
Google ScholarÂ
Menssen AJ, Hudson CA, Alonzo T, Gerbing R, Pardo L, Leonti A, et al. CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children’s Oncology Group. Haematologica. 2024;109:3182–93.
Google ScholarÂ

